Navigation Links
YM BioSciences presents CYT387 and CYT997 data at international cancer conference
Date:2/11/2010

ternational approval, marketing and commercialization.

Nimotuzumab is a humanized monoclonal antibody in development worldwide, targeting multiple tumor types primarily in combination with radiation and chemoradiation. It is importantly differentiated from all other currently marketed EGFR-targeting agents due to its remarkably benign side-effect profile. Nimotuzumab's anti-tumor activity has led to its approval for marketing in 23 countries. In more than 9,000 patients reported as having been treated with nimotuzumab worldwide to date, Grade IV incidents of radiation dermatitis and incidents of severe rash have been only rarely observed and reports of the other severe side-effects that are typical of EGFR-targeting molecules have been equally rare. Nimotuzumab is licensed to YM's majority-owned, Canadian subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and was developed at the Center of Molecular Immunology. The products discovered by YM's recently acquired Australian subsidiary, YM Australia (formerly Cytopia Limited), include the JAK 1/2 inhibitor CYT387, and the novel VDA molecule CYT997. Both were discovered internally at Cytopia based on research led by Dr Andrew Wilks who identified the JAK 1/2 kinase enzymes. Both products are currently in clinical development. YM is developing AeroLEF for the treatment of moderate to severe acute pain. The product is differentiated from other approaches using opioids because patients are able to individually control the analgesia required for their differing intensities of pain. AeroLEF has met all endpoints in each of its trials including a randomized Phase II trial and is currently being prepared for late-stage development internationally.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results,
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. YM BioSciences granted two US patents for AeroLEF(R)
2. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
3. YM BioSciences reports second quarter 2010 operational and financial results
4. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
5. Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
6. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
7. Cellectricon Files Patent Infringement Suit Against Fluxion Biosciences
8. YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA
9. YM BioSciences announces result of Cytopia shareholder vote
10. Profectus Biosciences to Present at Key Investor Conference in January 2010
11. David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Boston, Mass. (PRWEB) July 10, 2014 ... , today announced that Alan Swahn, a former vice ... Terascala’s executive team as vice president of marketing. Terascala’s ... from Dell and NetApp create the highest performance and ... has been appointed to guide Terascala’s channel expansion and ...
(Date:7/10/2014)... OMICS Group’s 5th International conference and exhibition ... at Double Tree by Hilton Beijing, China is all ... & Bioanalytical research methods only to facilitate improved living ... Dr. Srinubabu Gedela, MD of OMICS Group Inc has ... one in bringing a unique and international mix of ...
(Date:7/10/2014)... , July 10, 2014  Franciscan ... use of capnography for respiratory monitoring outside ... of healthcare leaders in embracing state-of-the-art patient ... effectively patients are breathing and can alert ... By measuring the amount of carbon dioxide ...
(Date:7/10/2014)... 2014 /PRNewswire-iReach/ -- Tute Genomics, the leader ... an agreement with Lineagen, Inc., to provide ... Dx PLUS.  Lineagen, focused on the ... currently offers FirstStep Dx PLUS, a ... by healthcare providers as a first-line genetic ...
Breaking Biology Technology:Terascala Expands Executive Team 2Terascala Expands Executive Team 3A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4
... measure the ability to tune out negativity, author and ... southeastern Wisconsin technology professionals. , ,Kawasaki, managing partner of ... of the Start" and several other business books, gave ... eInnovate. He poked some good-natured fun at politicians, Microsoft ...
... Standard Networks, Inc., a Madison software developer, achieved ... months of 2006, thanks largely to a 125 percent ... message transfer management products. , ,Citing its privately held ... MOVEit, but said Standard Network's overall revenues increased by ...
... Wis. - In a move to comply with ... Security, an Internet security provider, as a partner in ... union clients. , ,The move comes as financial institutions ... comply with Federal Financial Institutions Examination Council requirements to ...
Cached Biology Technology:Beating back the bozos is an innovation must, says Kawasaki 2
(Date:7/14/2014)... in 2005, controls T-cell activation and differentiation by ... so, it helps to guarantee immunological tolerance and ... that can lead to autoimmune disease. Roquin is ... five and ten per cent of the population. ... environmental influences when a genetic predisposition exists. Only ...
(Date:7/14/2014)... than 140 years ago, Charles Darwin noticed something peculiar ... species are more tame, and they also tend to ... ears, patches of white fur, and more juvenile faces ... this pattern has proved elusive, but now, in a ... a new hypothesis has been proposed that could explain ...
(Date:7/13/2014)... women suggests that experiencing one or more stressful events ... slow the body,s metabolism, potentially contributing to weight gain. ... stressors before giving them a meal consisting of 930 ... measured their metabolic rate how long it took ... took measures of blood sugar, triglycerides, insulin and the ...
Breaking Biology News(10 mins):Molecular mechanisms underlying the prevention of autoim-munity by Roquin revealed 2Domestication syndrome: White patches, baby faces and tameness 2Weighty issue: Stress and high-fat meals combine to slow metabolism in women 2Weighty issue: Stress and high-fat meals combine to slow metabolism in women 3Weighty issue: Stress and high-fat meals combine to slow metabolism in women 4
... at WEHI into a possible new cancer drug suggests ... less toxic than current chemotherapeutic drugs. , Dr David ... teams from WEHI's cancer research divisions have been assessing ... developed by US-based healthcare company, Abbott. , ...
... around the world keep a nervous eye on the spread ... Disease Organization (VIDO) has uncovered a key step in how ... team have discovered how a crucial pathway that supports the ... finding that could pave the way for new drugs and ...
... get lab results back from the doctor's office soon could ... of University of Georgia researchers has developed a diagnostic test ... RSV in 60 seconds or less. , In addition to ... issue of the journal Nano Letters ?could save lives by ...
Cached Biology News:Hope for a more effective and less toxic cancer drug 2U of S Vaccine and Infectious Disease Organization team discovers key step in flu virus replication 2Silver bullet: UGA researchers use laser, nanotechnology to rapidly detect viruses 2Silver bullet: UGA researchers use laser, nanotechnology to rapidly detect viruses 3
...
Cag-A (IgG) -Ab EIA Sample Size: 10 l...
... RNaseOUT Recombinant Ribonuclease Inhibitor is ... pancreatic-type ribonucleases such as RNase ... RNaseOUT Recombinant Ribonuclease Inhibitor is ... molecular weight ~52 kDa. RNaseOUT ...
... RNase Inhibitor (Ribonuclease inhibitor) is ... used to inhibit RNase activity. ... or endonuclease activity. , ... of RNA template , ...
Biology Products: